Retrospective 28,855 remdesivir patients with PSM matched controls, showing lower mortality with treatment.
Mozaffari et al., 10/1/2021, retrospective, USA, North America, peer-reviewed, 12 authors.
risk of death, 12.0% lower, RR 0.88, p = 0.003, treatment 4,441 of 28,855 (15.4%), control 5,499 of 28,855 (19.1%), adjusted per study, 28 days, PSM, Cox proportional hazards.
risk of death, 24.0% lower, RR 0.76, p < 0.001, treatment 3,057 of 28,855 (10.6%), control 4,437 of 28,855 (15.4%), adjusted per study, 14 days, PSM, Cox proportional hazards.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.